GlassScriptPhysician profile
Hesham Hazin
NPI 1235369307
$38,391.26
in general payments reported to CMS, 2019-2025
38 companies · $185 in 2025
The $185 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $1,383 · 2021: $9,200 · 2022: $7,535 · 2023: $855 · 2024: $1,272 · 2025: $185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $1,169 · Food and Beverage: $1,143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $1,168.75 |
| Food and Beverage | $1,142.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $34,669.84 | 2019-2022 | |
| Myriad Genetic Laboratories, INC. | $1,168.75 | 2024 | Myrisk, Precisetumor |
| Myriad Women'S Health, INC. | $347.00 | 2023 | Precisetumor |
| Merck Sharp & Dohme LLC | $238.98 | 2019-2025 | Keytruda, Keytruda Qlex |
| E.R. Squibb & Sons, L.L.C. | $174.79 | 2019-2023 | |
| Siemens Medical Solutions USA, INC. | $145.48 | 2023 | Mammomat Revelation |
| Incyte Corporation | $141.93 | 2019 | |
| Lilly USA, LLC | $138.71 | 2019-2025 | Verzenio |
| Beigene USA, INC. | $125.00 | 2023 | Brukinsa |
| Novartis Pharmaceuticals Corporation | $112.58 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $112.12 | 2019 | |
| Amgen INC. | $102.52 | 2019 | |
| Pfizer INC. | $93.88 | 2019-2025 | |
| Janssen Biotech, INC. | $80.49 | 2019-2025 | Darzalex, Tecvayli |
| Pinnacle Biologics, INC | $75.40 | 2024 | Photofrin |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $71.65 | 2019 | |
| Coherus Oncology, INC. | $70.51 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.67 | 2019-2025 | |
| Rigel Pharmaceuticals, INC. | $55.56 | 2019-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $52.47 | 2022-2023 | Imbruvica |
| Daiichi Sankyo INC. | $38.14 | 2019-2025 | Enhertu |
| Tersera Therapeutics LLC | $36.20 | 2019 | |
| Eisai INC. | $30.35 | 2019 | |
| Sobi, INC | $28.17 | 2022 | |
| Dova Pharmaceuticals | $24.42 | 2021 | |
| Taiho Oncology, INC. | $23.64 | 2019 | |
| Abbvie INC. | $20.86 | 2025 | |
| Aveo Pharmaceuticals, INC. | $16.16 | 2025 | |
| Glaxosmithkline, LLC. | $16.16 | 2025 | Ojjaara |
| Myovant Sciences INC. | $15.63 | 2021 | |
| Astellas Pharma US INC | $15.63 | 2025 | Cresemba |
| Teleflex LLC | $14.33 | 2019 | |
| Celgene Corporation | $13.76 | 2019 | |
| Emmaus Medical, INC. | $13.25 | 2022 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Clovis Oncology, INC. | $11.70 | 2019 | |
| Exelixis INC. | $11.06 | 2019 | |
| Qorumpartners | $9.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hesham Hazin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.